GAD-7 Scoring

What the GAD-7 measures

The Generalized Anxiety Disorder-7 (GAD-7) is a brief, validated self-report questionnaire used to screen for and measure the severity of generalized anxiety disorder (GAD). Developed by Drs. Robert L. Spitzer, Kurt Kroenke, Janet B.W. Williams, and Bernd Löwe, the GAD-7 has become one of the most widely used anxiety screening tools in clinical practice and research.

The GAD-7 asks patients to rate how often they've been bothered by seven core anxiety symptoms over the past two weeks, including feeling nervous, inability to stop worrying, excessive worry, restlessness, difficulty relaxing, irritability, and feeling afraid. These items align with DSM-5-TR criteria for generalized anxiety disorder.

Each item is scored from 0 (not at all) to 3 (nearly every day), yielding a total score range of 0-21. Research has demonstrated that the GAD-7 has excellent internal consistency and good test-retest reliability. It's also shown validity for screening panic disorder, social anxiety disorder, and post-traumatic stress disorder, making it a versatile tool in mental health assessment.

GAD-7 beyond generalized anxiety

While designed for GAD, research supports using the GAD-7 to screen for panic disorder, social anxiety disorder, and PTSD. A score ≥8 suggests probable anxiety disorder across these conditions.

How the GAD-7 was developed

Developed in 2006, the GAD-7 is one of the most commonly used measures for anxiety. There are many other validated measures that exist to identify and monitor anxiety, including the Hamilton Anxiety Scale (HAM-A), Hospital Anxiety and Depression Scale (HADS), Covi Anxiety Scale, Clinical Anxiety Scale (CAS), State-Trait Anxiety Inventory (STAI), Generalized Anxiety Disorder Questionnaire-IV (GAD-Q-IV), and World Health Organization Composite International Diagnostic Interview Short-Form (CIDI-SF), among others.

To create the measure, the authors identified an initial list of potential items that could compose the scale. They started with 9 items that each corresponded to symptom criteria for generalized anxiety disorders within the DSM-IV, plus 4 additional items based on a fulsome review of other existing anxiety scales. Their goal was to identify the items that were most effective at measuring anxiety symptoms and shorten the length of the measure, in order to reduce assessment burden on patients and increase completion rates, while ensuring strong reliability and procedural, construct, and diagnostic criterion validity.

In order to do so, they completed a criterion-standard study that compared GAD self-report scale diagnoses to independent diagnoses made by mental health professionals, as well as functional status measures, disability days, and health care use. There were two phases to this project, the first being to identify the scale items and determine cut off scores, and the second focused on testing its reliability. The final 7 items were chosen based on them having the highest correlation with the total 13-item scale score (Spitzer et al., 2006).

Who is the GAD-7 Assessment for?

Review the list below to determine if this assessment should be used with your client. If you answer no to the question below, the GAD-7 is a good fit for your client.

1. Is your client under 14? If they are, please refer to the Child Depression & Anxiety (RCADS 25) measure.

Note: The GAD-7 has shown good sensitivity, specificity, reliability, and factorial, construct, and concurrent validity in many specific subgroups, including patients with chronic migraines (Seo and Park, 2015), drug and alcohol use challenges (Delgadillo et al., 2012), as well as elderly people (Wild et al., 2014), and pregnant women (Zhong et al., 2015). Seeing that it is short and easy to administer, it is also effective in multiple settings, such as remote health surveys, epidemiologic studies, primary care, and in-person settings (García-Campayo et al., 2012).

How to administer the GAD-7

The GAD-7 asks respondents how often, during the last 2 weeks, they were bothered by each of the 7 items. Response options are “not at all,” “several days,” “more than half the days,” and “nearly every day,” each scored as 0, 1, 2, and 3.

Though this is a self-report measure, validity is not compromised if the therapist reads the questions to the client to help them complete it. The scale can be administered by non-clinical staff, but must be interpreted by a licensed clinician. If administering the scale over the phone, it is important to ensure the client can recall and implement the response scale when scoring each item. While the scale (shown below) has intentionally developed to be easy to understand for clients, it may be beneficial to review the scale questions when first introduced and to revisit or check in on a clients’ interpretation of questions at regular intervals throughout their time in care.

Watch this video from Buckinghamshire Healthcare NHS Trust, filmed at Mandeville Hospital, to see an example of the assessment being administered verbally in session. Notice how the client is actively interpreting the questions and discussing how his answers may apply, while the provider is asking clarifying questions when necessary to ensure the most accurate responses. This is an important process to ensure the client has an appropriate interpretation of the question and can recall moving forward.

Video Credit: buckshospitals

Patients independently rate how often anxiety symptoms have bothered them over the past 2 weeks. Available in paper or digital format for convenient administration.

Takes 2-5 minutes to complete. Scoring is straightforward, sum the seven items for a total score between 0 and 21.

Administer at baseline and periodically throughout treatment (typically every 2-4 weeks) to track symptom progression and treatment effectiveness. Explore our platform features for automated tracking.

The GAD-7 includes two additional questions about functional impairment and difficulty rating, providing context for score interpretation.

• Clarify the past 2 weeks timeframe before patients begin
• Review responses with patients to understand context and symptom patterns
• Combine scores with clinical assessment, the GAD-7 is a screening tool, not a diagnostic substitute
• Consider co-administering with PHQ-9 to screen for depression and anxiety concurrently, see the PHQ-9 vs GAD-7 vs PCL-5 comparison
• When anxiety is affecting daily functioning, pair the GAD-7 with the WSAS to quantify functional impairment alongside symptom severity
• Available in multiple validated translations for diverse patient populations

GAD-7 scoring and interpretation

Screening Cutoff Scores

GAD-7 total scores map to four severity bands:

• 0–4 — minimal anxiety
• 5–9 — mild anxiety
• 10–14 — moderate anxiety
• 15–21 — severe anxiety

The validated primary cut-point is ≥10 (sensitivity 89%, specificity 82% for generalized anxiety disorder; Spitzer et al., 2006). At the ≥10 threshold the GAD-7 also functions as a screen for three other anxiety disorders (Kroenke et al., 2007):

• Panic disorder — sensitivity 74%, specificity 81%
• Social anxiety disorder — sensitivity 72%, specificity 80%
• Post-traumatic stress disorder — sensitivity 66%, specificity 81%

A lower cut-point of ≥8 (pooled sensitivity 83%, specificity 84% for generalized anxiety disorder) is supported when missing cases is costlier than over-referral; cut-offs of 7 to 10 perform similarly (Plummer et al., 2016).

Monitoring Treatment Response

A change of 4 points or more is considered clinically significant. Track scores over time to evaluate whether interventions are reducing anxiety symptoms.

If anxiety scores remain elevated after 6-8 weeks of treatment, consider adjusting medication dosage, changing therapeutic approach, or consulting with a specialist.

Alternative cut-points and other anxiety disorders

Anxiety severity is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of “not at all”, “several days”, “more than half the days”, and “nearly every day”, respectively. The total GAD-7 score for the seven items can range from 0 to 21.

Though the authors recommend a cut-point of 10 for anxiety disorder screening, a recent a meta-analysis found acceptable accuracy for identifying Generalized Anxiety Disorder at cut-off scores of 7 to 10; at a cut-off of 8, pooled sensitivity was 83% and specificity 84% (Plummer et al., 2016). A score of 8 or greater represents a reasonable cut-point for identifying probable cases of Generalized Anxiety Disorder; however, further diagnostic assessment is warranted to determine the presence and type of anxiety disorder.

Screening for other anxiety disorders with the GAD-7

As mentioned previously, though the GAD-7 was designed primarily as a screening and severity measure for Generalized Anxiety Disorder, it also has moderately good operating characteristics for three other common anxiety disorders, including Panic Disorder, Social Anxiety Disorder, and Post-Traumatic Stress Disorder (Kroenke et al., 2007).

Performance of GAD-7 as Screening Tool for Anxiety Disorders (Using GAD-7 Score Cut-off of ≥ 10)

If other mental health challenges are present, consider adding a more specific measure that matches your client's presentation. For example, if a client is struggling with anxiety but you suspect it might be linked to PTSD, it can be beneficial to add a PTSD specific measure as it will be more sensitive to the unique symptoms present in this condition.

Diagnosis

If considering a diagnosis for anxiety, you should hold a clinical interview to determine if symptoms and distress levels outlined in GAD-7 results are clinically significant. It is also important to rule out other explanations or existing conditions that may lead to the presenting anxiety symptoms, including substance use, medical conditions, bereavement, or anything other factors that may be impacting your client.

Applying GAD-7 Results in Session

Now that you've started using the GAD-7 in session with your client(s), it's important to use the information you're gathering to inform clinical discussions, treatment decisions and improve both therapeutic alliance and clinical outcomes. Here are a few ways you can incorporate the GAD-7 results throughout care:

Treatment Planning

The information gathered by this measure can support and enrich clinical conversations, in order to give you a more complete picture of your clients experience. In addition to using results to inform care discussions, decisions and treatment planning, GAD-7 scores can also be used to inform additional techniques, interventions, exercises and referrals to improve care, based on each item of the GAD-7 (developed byVISN 4 MIRECC). Explore the additional suggestions below that can be considered for clients experiencing challenges with any of the 7 items:

1. Feeling nervous, anxious or on edge:

• Diaphragmatic breathing
• Thought monitoring
• Challenging maladaptive thoughts/feelings

2. Not being able to stop or control worrying.

• Identifying maladaptive thoughts/ feelings
• Challenging maladaptive thoughts/feelings
• Relaxation techniques

3. Worrying too much about different things.

• Thought monitoring
• Solvable vs. Unsolvable worries
• Identify possible solutions

4. Trouble relaxing

• Diaphragmatic breathing
• Autogenic Relaxation
• Guided Imagery

5. Being so restless that it is hard to sit still

• Diaphragmatic breathing
• Progressive Muscle Relaxation
• Guided imagery

6. Becoming easily annoyed or irritable

• Challenging maladaptive thoughts/feelings
• Breathing techniques
• Identify consequences to actions

7. Feeling afraid as if something awful might happen

• Thought monitoring
• Solvable vs. Unsolvable worries
• Challenging maladaptive thoughts/feelings

Monitoring Progress and Change

Using the GAD-7 throughout care helps both you and your client monitor progress in treatment and serves as an indicator of when things may not be improving. If a client scores less than 5 on 2 or more assessments in a row (with a minimum of 2 weeks between each assessment), there is good reason to believe that your client may be ready to discharge or transition into maintenance treatment.

Psychometric properties

The GAD-7 was developed in a criterion-standard study in 15 US primary care clinics: of 2,740 adults who completed the questionnaire, 965 had a telephone interview with a mental health professional. The scale showed good reliability and criterion, construct, factorial, and procedural validity; increasing scores were strongly associated with functional impairment and disability days, and self-report and interviewer-administered versions agreed well (Spitzer et al., 2006). In the same primary care sample, the GAD-7 and its two core items (GAD-2) performed well as screening tools for all four anxiety disorders (area under the curve 0.80 to 0.91; Kroenke et al., 2007). A meta-analysis of 12 samples (5,223 participants) found acceptable accuracy for generalized anxiety disorder at cut-offs of 7 to 10 (Plummer et al., 2016).

Validity

• 89% sensitivity for GAD at cutoff ≥10
• 82% specificity for GAD at cutoff ≥10
• ≥8 suggests probable panic disorder, social anxiety disorder, or PTSD
• AUC 0.906 for GAD diagnosis (Spitzer et al., 2006)

Reliability

• α = 0.92 Cronbach's alpha (excellent internal consistency)
• r = 0.83 test-retest intraclass correlation
• ≥4 pts clinically significant change threshold
• 13+ validated age range (adolescents to older adults)

Limitations

• Screening, not diagnosis. A positive screen calls for a clinical interview to confirm clinical significance and rule out other explanations such as substance use, medical conditions, or bereavement.
• Designed for GAD. Accuracy for panic disorder, social anxiety disorder, and PTSD is lower than for generalized anxiety disorder; add a condition-specific measure when one of these is suspected.
• Cut-point choice. Studies support cut-offs from 7 to 10, so the threshold should match the setting and the cost of missed cases (Plummer et al., 2016).
• Self-report. Scores depend on the client's recall of the past two weeks and understanding of the response scale, especially when administered by phone.
• Validation setting. The original validation was in US adult primary care patients (Spitzer et al., 2006).

Population Context

Documenting GAD-7 scores in clinical notes?

GAD-7 scores belong in the Objective section alongside PHQ-9 when both are administered. See our SOAP notes guide and therapy progress notes guide for templates and examples.

GAD-7 vs PHQ-9 vs PCL-5

When anxiety symptoms overlap with depression or trauma presentations, GAD-7 and PHQ-9 are frequently co-administered. For combined depression, anxiety, and stress screening in a single questionnaire, the DASS-21 is a useful alternative. For a structured comparison of when to use each scale and how to interpret concurrent scores, see the PHQ-9 vs GAD-7 vs PCL-5 comparison guide.